Comparison of automated von Willebrand factor activity assays

Timm, Annette; Hillarp, Andreas; Philips, Malou; Goetze, Jens P.

doi:10.1016/j.thromres.2015.01.027

Cited by 9 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). It is noted that a similar small difference has been demonstrated by some [20,30,31] but not all [19] investigators for GPIbM. The reason for the discrepancy is not clear; however, the small differences would have no impact in clinical practice.…”

Section: In Panel C)mentioning

confidence: 76%

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study

Szederjesi

Baronciani

Budde³

et al. 2018

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background Several new assays have become available to measure von Willebrand factor (VWF) activity. The new assays appear to have improved performance characteristics compared with the old reference standard, ristocetin cofactor activity (VWF:RCo), but information is limited about how they compare with VWF:RCo and each other. Methods The von Willebrand factor Subcommittee of the International Society for Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) designed a collaborative study involving expert laboratories from several countries to compare available tests with each other and with VWF:RCo. Eight laboratories from five countries were provided with blinded samples from normal healthy individuals and well-characterized clinical cases. Laboratories measured VWF activity using all tests available to them; data from six laboratories, not affected by thawing during transportation, are included in this study. Results All tests correlated well with VWF:RCo activity (r-values ranged from 0.963 to 0.989). Slightly steeper regression lines for VWF:Ab and VWF:GPIbM were clinically insignificant. The new assays showed improved performance characteristics. Of the commercially available assays, the VWF:GPIbR using the AcuStar system was the most sensitive and could reliably detect VWF activity below 1 IU dL . The lower limit of the measuring interval for the VWF:GPIbM and the VWF:GPIbR assays was in the 3-4 and 3-6 IU dL range, respectively. Inter-laboratory variation was also improved for most new assays. Conclusion All VWF activity assays correlated well with each other and the VWF:RCo assay. The slight differences in characteristics found in the COMPASS-VWF study will assist the VWF community in interpreting and comparing activity results.

show abstract

Section: In Panel C)mentioning

confidence: 76%

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study

Szederjesi

Baronciani

Budde³

et al. 2018

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…An additional Siemens Innovance 'VWF activity assay', or 'VWF Ac', representing a direct GPIb binding assay, and previously validated by us and by others as representing a similar assay profile to VWF:RCo [12][13][14][15], was also included in this study for comparative evaluation purposes.…”

Section: Evaluation Methodsmentioning

confidence: 99%

“…The majority of laboratories perform FVIII coagulant (FVIII:C) and VWF antigen (VWF:Ag) [1,5], which respectively measure levels of FVIII activity and VWF protein, the latter most commonly using either ELISA (enzyme linked immunosorbent assay) or LIA (latex-immuno-assay) technologies. VWF 'activity' can be assessed by a wide variety of methodologies, including ristocetin cofactor (VWF:RCo), collagen binding (VWF:CB) and newer direct GPIb binding assays (e.g., Siemens INNOVANCE VWF Ac) [8,[12][13][14][15]. Which assays, and how many of these laboratories use as a diagnostic test panel, and what methodology laboratories employ within each individual assay, strongly impacts the accuracy of VWD identification, diagnosis and typing [5,8].…”

Section: Introductionmentioning

confidence: 99%

“…VWF:RCo represents the most commonly performed activity based test [1,2,[4][5][6][7][8][9][10], usually by platelet agglutination assay using aggregometry or automated methods with modern hemostasis instruments, and sometimes by LIA technology [8]. Direct GPIb binding assays provide similar values to VWF:RCo in published studies [8,[12][13][14][15]. VWF:CB, although typically performed by fewer laboratories, is nonetheless an important activity assay, usually performed by ELISA [1,2,[4][5][6][7][8][9][10], and whose omission will compromise VWD identification, diagnosis and typing [5,8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease

Favaloro

Mohammed

2016

Thrombosis Research

104

View full text Add to dashboard Cite

von Willebrand disease (VWD) is reportedly the most common bleeding disorder and arises from deficiency and/or defects of von Willebrand factor (VWF). Laboratory diagnosis and typing of VWD has important management implications and requires a wide range of tests, including VWF antigen (VWF:Ag) and various activities, involving differential identification of qualitative vs quantitative VWF defects. We have assessed a new hemostasis instrument, the chemiluminescent assay based ACL AcuStar™, and an associated HemosIL AcuStar three test panel comprising VWF:Ag, VWF ristocetin cofactor (VWF:RCo) and VWF collagen binding (VWF:CB) (Instrumentation Laboratory, Bedford, Ma. USA) for ability to identify VWD, to help provisionally type VWD, and for potential use in therapy monitoring. This test system was compared to previously evaluated and validated test systems including VWF:RCo on CS-5100 and BCS analyzers, the new Siemens INNOVANCE assay (VWF Ac) on CS-5100, and VWF:Ag and VWF:CB assays performed by automated ELISA. We employed a large total sample test set (n=535) comprising plasma and platelet-lysate samples from individuals with and without VWD, some on treatment, normal plasmas, and normal and pathological controls. We also evaluated desmopressin (DDAVP) responsiveness, plus differential sensitivity to reduction in high molecular weight (HMW) VWF. The chemiluminescent test panel (VWF:Ag, VWF:RCo, VWF:CB) showed good comparability to similar assays performed by alternate methods, and broadly similar data for identification of VWD, provisional VWD type identification, DDAVP and VWD therapy, and HMW VWF sensitivity, although some notable differences were evident. The chemiluminescent system showed best low level VWF sensitivity, and lowest inter-assay variability, compared to all other systems. In conclusion, we have validated theACL AcuStar and the chemiluminescent HemosIL AcuStar VWF test panel for use in VWD diagnostics, and have identified some favorable characteristics that may improve the future diagnosis of VWD.

show abstract

“…The detection limit for vWF activity was 0.07 to 4.80 kIU/L, with the coefficient of variation (CV max ) of 6.9% and limit of detection of 0.04I U/mL. 13…”

Section: Von Willebrand Factormentioning

confidence: 93%

von Willebrand Factor and Prekallikrein in Plasma Are Associated With Thrombus Volume in Abdominal Aortic Aneurysms

Ghulam

Bredahl

Gram

et al. 2016

Vasc Endovascular Surg

Self Cite

View full text Add to dashboard Cite

show abstract

Comparison of automated von Willebrand factor activity assays

Cited by 9 publications

References 23 publications

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study

Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease

von Willebrand Factor and Prekallikrein in Plasma Are Associated With Thrombus Volume in Abdominal Aortic Aneurysms

Contact Info

Product

Resources

About